摘要
目的应用荟萃方法评价重组组织型纤溶酶原激活剂治疗下肢深静脉血栓形成的疗效。方法计算机检索中国生物医学文献数据库(CBM)、中国期刊全文数据库(CNKI)和维普全文电子期刊及ovid(1966至2009)、Medline(1966至2009年)、EMBAS(1994至2009年)、Cochrane临床对照试验资料库,辅以手工检索发表及未发表的有关重组组织型纤溶酶原激活剂治疗下肢深静脉血栓形成的临床随即对照试验,以Cochrane推荐的RevMan4.3软件进行分析,采用比值比作为效应合并量。结果共纳入4个随即对照试验(RCT),荟萃分析结果显示,以治疗后有效率(静脉造影复查溶栓>50%)和出血并发症发生率为临床观测指标,重组组织型纤溶酶原激活剂组和对照组相比合并比值比分别是[OR7.9795%CI(2.23,28.44)]和[OR6.6095%CI(1.85,23.52)]差异有统计学意义。结论以本项荟萃分析为基础,重组组织型纤溶酶原激活剂治疗下肢深静脉血栓形成对静脉再通率的提高程度所获益处不足以抵消出血率的升高,对其疗效尚不能得出最后结论。
Objective To make impersonal evaluation on the effect ofrt-PA for deep venous thrombosis. Method We search all randomized control trials of rt-PA for deep venous thrombosis （DVT） from CBM, CNKI, VIE ovid（1966-2009）, Medline （1990-2009）, EMBASE（1994-2009）, Cochrane Central Register of Controlled Trials, we also hand-searched relevant journals, Meta-analysis was conducted combining with odds ratio of individual studies, RevMan 4.3 was used in the analysis. Results 4 RCT was include in the comparision and criteria, the result of analysis showed that rt-PA could raise both the clinical effective ratio（〉50%lysis of thrombus by venograpy） [OR 7.97 95%CI（2.23, 28.44）]and the rate of bleeding[OR 6.60 95%CI（1.85, 23.52）]. Conclusion The present meta-analysis suggests that the increased clinical effective ratio by rt-PA could not match the benefit on increased rate of bleeding. So we can not make a final conclusion on clinical effect of rt-PA.
出处
《中国医药指南》
2010年第6期31-34,共4页
Guide of China Medicine
